ImmunoGen, Inc. Announces Webcast of Presentation at J.P. Morgan 29th Annual Healthcare Conference
January 03 2011 - 5:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biotechnology company that develops targeted antibody-based
anticancer products using its antibody expertise and Targeted
Antibody Payload (TAP) technology, today announced that President
and CEO, Daniel Junius, will present at the J.P. Morgan 29th Annual
Healthcare Conference at 9:00 am PT/12:00 noon ET on January 10,
2011. The presentation will contain an update on IMGN901
development plans, including current plans related to Merkel cell
carcinoma.
A live webcast of the presentation can be accessed through the
“Investor Information” section of the Company’s website,
www.immunogen.com; a replay of the presentation will be available
at the same location for two weeks.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies and
potent cancer-cell killing agents. The Company's TAP technology
uses monoclonal antibodies to deliver one of ImmunoGen's
proprietary cancer-cell killing agents specifically to tumor cells.
There are currently seven TAP compounds in the clinic, with a
wealth of clinical data reported with the technology. ImmunoGen’s
collaborative partners include Amgen, Bayer Schering Pharma, Biogen
Idec, Biotest, Genentech (a member of the Roche Group), Novartis,
and sanofi-aventis. The most advanced compound using ImmunoGen's
TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing
through the Company's collaboration with Genentech. More
information about ImmunoGen can be found at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024